Bcl-2: research progress from target to launched drug
10.16438/j.0513-4870.2017-1210
- VernacularTitle:Bcl-2:从靶标到上市药物的研究进展
- Author:
Xiao-xian LI
1
;
Ren-shuai LIU
1
;
Hao FANG
1
Author Information
1. Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Jinan 250012, China
- Publication Type:REVIEWS
- Keywords:
apoptosis;
Bcl-2 inhibitor;
protein-protein interaction
- From:
Acta Pharmaceutica Sinica
2018;53(4):509-517
- CountryChina
- Language:Chinese
-
Abstract:
Apoptosis is an important self-stabilizing mechanism of multicellular organisms, which plays a vital role in the development of normal living organisms and the maintenance of tissue homeostasis. The abnormalities in apoptosis often lead to body lesions including tumors. Studies have shown that Bcl-2 protein with anti-apoptosis activity is an important target in the treatment of cancer. After nearly two decades of efforts, many small molecule Bcl-2 inhibitors have been discovered to induce cell apoptosis. The small-molecule Bcl-2 inhibitor, venetoclax, was developed based on fragment-based drug design strategy and approved by the FDA in 2016 for clinical application. This agent is the first approved small-molecule drug inhibiting Bcl-2 through protein-protein interaction to induce cell apoptosis. The achievement of venetoclax benefits from a combination of drug discovery technologies and represents a milestone in the history of drug discovery. In this review we will introduce the current progress in Bcl-2 inhibitors.
